retatrutide phase 2 trial Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide Shows Promising Results in

Precision is also paramount in terms of getting optimal treatment for people, and the appeal of different treatments might differ amongst people. GLP-1 Treatments Face Hurdles While GLP-1s offer promising benefits for some patients, significant barriers remain regarding supply, cost, and insurance coveragechallenges that Saunders describes as humongous limitations. Novo Nordisks Ozempic and Wegovy have been on the FDAs drug shortage list since 2022

Lipid panels offer additional metabolic insight since triglyceride levels correlate with insulin resistance

Contact your healthcare provider if you experience any of these symptoms

GLP-1 medications mimic this natural hormone, but in a longer-acting and more reliable way

Shot day (and the day after): soft, low-fat, small plates

It raises energy expenditure, meaning your body burns more calories even at rest